Idebenone treatment in Leber's hereditary optic neuropathy: rationale and efficacy

Bibliography

• Leber T. Ueber hereditaere und congenital angelegte Sehnervenleiden. Graefes Arch Clin Exp Ophthalmol 1871;17:249-91
   Google Scholar
• Man PYW, Griffiths PG, Brown DT, The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet 2003;72(2):333-9
   PubMed Web of Science ®Google Scholar
• Mascialino B, Leinonen M, Meier T. Meta-analysis of the prevalence of Leber hereditary optic neuropathy mtDNA mutations in Europe. Eur J Ophthalmol 2012;22(3):461-5
   PubMed Web of Science ®Google Scholar
• Fraser JA, Biousse V, Newman NJ. The neuro-ophthalmology of mitochondrial disease. Surv Ophthalmol 2010;55(4):299-34
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet 2009;46(3):145-58
   PubMed Web of Science ®Google Scholar
• Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res 2004;23(1):53-90
   PubMed Web of Science ®Google Scholar
• Wallace DC, Singh G, Lott MT, Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988;242:1427-30
   PubMed Web of Science ®Google Scholar
• Johns DR, Neufeld MJ, Park RD. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem Biophys Res Commun 1992;187(3):1551-7
   Google Scholar
• Huoponen K, Vilkki J, Aula P, A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. Am J Hum Genet 1991;48(6):1147-53
   PubMed Web of Science ®Google Scholar
• Beretta S, Wood JP, Derham B, Partial mitochondrial complex I inhibition induces oxidative damage and perturbs glutamate transport in primary retinal cultures: relevance to Leber Hereditary Optic Neuropathy (LHON). Neurobiol Dis 2006;24(2):308-17
   Google Scholar
• Howell N. Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve. Vision Res 1998;38:1495-504
   PubMed Web of Science ®Google Scholar
• Zanna C, Ghelli A, Porcelli AM, Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and endonuclease G. Apoptosis 2005;10(5):997-1007
   PubMedGoogle Scholar
• Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res 2004;23:53-89
   PubMed Web of Science ®Google Scholar
• Sadun AA, Morgia CL, Carelli V. Leber's hereditary optic neuropathy. Curr Treat Options Neurol 2011;13(1):109-17
   PubMed Web of Science ®Google Scholar
• Guy J, Qi X, Pallotti F, Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy. Ann Neurol 2002;52(5):534-42
   PubMed Web of Science ®Google Scholar
• Ellouze S, Augustin S, Bouaita A, Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 2008;83(3):373-87
   PubMed Web of Science ®Google Scholar
• Oca-Cossio J, Kenyon L, Hao H, Moraes CT. Limitations of allotopic expression of mitochondrial genes in mammalian cells. Genetics 2003;165(2):707-20
   Google Scholar
• Perales-Clemente E, Fernandez-Silva P, Acin-Perez R, Allotopic expression of mitochondrial-encoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task? Nucleic Acids Res 2011;39(1):225-34
   PubMed Web of Science ®Google Scholar
• Lam BL, Feuer WJ, Abukhalil F, Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1. Arch Ophthalmol 2010;128(9):1129-35
   PubMedGoogle Scholar
• Sadun AA, Chicani CF, Ross-Cisneros FN, Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol 2012;69(3):331-821
   PubMed Web of Science ®Google Scholar
• Okamoto K, Matsumoto M, Watanabe M, Effects of 6-(omega-substituted alkyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinones and related compounds on mitochondrial succinate and reduced nicotinamide adenine dinucleotide oxidase systems. Chem Pharm Bull (Tokyo) 1985;33(9):3745-55
   Google Scholar
• Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010;99(3):246-55
   PubMed Web of Science ®Google Scholar
• Suno M, Nagaoka A. Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun 1984;125(3):1046-52
   Google Scholar
• Suno M, Shibota M, Nagaoka A. Effects of idebenone on lipid peroxidation and hemolysis in erythrocytes of stroke-prone spontaneously hypertensive rats. Arch Gerontol Geriatr 1989;8(3):307-11
   Google Scholar
• Suno M, Nagaoka A. Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate. Arch Gerontol Geriatr 1989;8(3):291-7
   Google Scholar
• Suno M, Nagaoka A. Inhibition of brain mitochondrial swelling by idebenone. Arch Gerontol Geriatr 1989;8(3):299-305
   Google Scholar
• Mordente A, Martorana GE, Minotti G, Giardina B. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol 1998;11(1):54-63
   PubMed Web of Science ®Google Scholar
• Sortino MA, Battaglia A, Pamparana F, Neuroprotective effects of nicergoline in immortalized neurons. Eur J Pharmacol 1999;368(2):285-90
   Google Scholar
• Jauslin ML, Wirth T, Meier T, Schoumacher F. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet 2002;11(24):3055-63
   Google Scholar
• Jauslin ML, Meier T, Smith RA and Murphy MP. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003;17(13):1972-4
   PubMedGoogle Scholar
• Jauslin ML, Vertuani S, Durini E, Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia. Mol Cell Biochem 2007;302(1-2):79-85
   PubMed Web of Science ®Google Scholar
• Gil J, Almeida S, Oliveira CR, Rego AC. Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis. Free Radic Biol Med 2003;35(11):1500-14
   Google Scholar
• Sugiyama Y, Fujita T, Matsumoto M, Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J Pharmacobiodyn 1985;8(12):1006-17
   Google Scholar
• Imada I, Fujita T, Sugiyama Y, Effects of idebenone and related compounds on respiratory activities of brain mitochondria, and on lipid peroxidation of their membranes. Arch Gerontol Geriatr 1989;8(3):323-41
   Google Scholar
• Degli Esposti MD, Ngo A, Ghelli A, The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys 1996;330(2):395-400
   Google Scholar
• Lenaz G, Bovina C, D'Aurelio M, Role of mitochondria in oxidative stress and aging. Ann NY Acad Sci 2002;959:199-213
   PubMed Web of Science ®Google Scholar
• Briere JJ, Schlemmer D, Chretien D, Rustin P. Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun 2004;316(4):1138-42
   PubMed Web of Science ®Google Scholar
• James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 2005;280(22):21295-312
   PubMed Web of Science ®Google Scholar
• Rauchova H, Drahota Z, Bergamini C, Modification of respiratory-chain enzyme activities in brown adipose tissue mitochondria by idebenone (hydroxydecyl-ubiquinone). J Bioenerg Biomembr 2008;40(2):85-93
   Google Scholar
• Fato R, Bergamini C, Leoni S, Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res 2008;33(12):2487-501
   Google Scholar
• King MS, Sharpley MS, Hirst J. Reduction of hydrophilic ubiquinones by the flavin in mitochondrial NADH:ubiquinone oxidoreductase (Complex I) and production of reactive oxygen species. Biochemistry 2009;48(9):2053-62
   Google Scholar
• Watzke N, Diekert K, Obrdlik P. Electrophysiology of respiratory chain complexes and the ADP-ATP exchanger in native mitochondrial membranes. Biochemistry 2010;49(48):10308-18
   Google Scholar
• Rauchova H, Mracek T, Novak P, Glycerol-3-phosphate dehydrogenase expression and oxygen consumption in liver mitochondria of female and male rats with chronic alteration of thyroid status. Horm Metab Res 2011;43(1):43
   Google Scholar
• Haefeli RH, Erb M, Gemperli AC, NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 2011;6(3):e17963
   PubMed Web of Science ®Google Scholar
• Giorgio V, Petronilli V, Prato M, The effects of idebenone on mitochondrial and cellular bioenergetics. Biophys J 2011;100:46
   Google Scholar
• Heitz FD, Erb M, Anklin C, Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. PLoS One 2012;7(9):e45182
   PubMed Web of Science ®Google Scholar
• Becker C, Bray-French K, Drewe J. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol 2010;6(11):1437-44
   PubMed Web of Science ®Google Scholar
• Bodmer M, Vankan P, Dreier M, Pharmacokinetics and metabolism of idebenone in healthy male subjects. Eur J Clin Pharmacol 2009;65(5):493-501
   PubMed Web of Science ®Google Scholar
• Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet 1992;340(8815):368-9
   Google Scholar
• Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol 2000;20(3):166-70
   PubMed Web of Science ®Google Scholar
• Cortelli P, Montagna P, Pierangeli G, Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci 1997;148(1):25-31
   Google Scholar
• Carelli V, Ghelli A, Cevoli S, Idebenone therapy in Leber's hereditary optic neuropathy: report of six cases. Neurology 1998a;50:A4
   Google Scholar
• Carelli V, Barboni P, Zacchini A, Leber's Hereditary Optic Neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci 1998b;160(2):183-8
   PubMed Web of Science ®Google Scholar
• Carelli V, Valentino ML, Liguori R, Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases. J Neurol Neurosurg Psychiatry 2001;71(6):813-16
   Google Scholar
• Barnils N, Mesa E, Munoz S, Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy. Arch Soc Esp Oftalmol 2007;82:377-80
   PubMedGoogle Scholar
• Klopstock T, Yu-Wai-Man P, Dimitriadis K, A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011;134(9):2677-86
   Google Scholar
• Carelli V, La Morgia C, Valentino ML, Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011;134(9):e188-8
   Google Scholar
• Klopstock T, Metz G, Yu-Wai-Man P, Persistence of the treatment of idebenone in Leber's hereditary optic neuropathy. Brain 2013; In press
   Google Scholar
• Fsadni M, Klopstock T, Metz G, Persistence of treatment effect of idebenone in Leber's Hereditary Optic Neuropathy. Acta Ophthalmol 2012; doi:10.1111/j.1755-3768.2012.T132.x
   Google Scholar
• Sabet-Peyman EJ, Khaderi KR, Sadun AA. Is Leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case. J Neuroophthalmol 2012;32(1):54-7
   PubMed Web of Science ®Google Scholar
• McGuffin M, Young AL. Premarket notifications of new dietary ingredients – a ten year review. Food Drug Law J 2004;59(1):229-44
   Google Scholar
• Bababeygy SR, Wang MY, Khaderi KR, Sadun AA. Visual improvement with the use of idebenone in the treatment of wolfram syndrome. J Neuroophthalmol 2012;32(4):386-9
   PubMed Web of Science ®Google Scholar
• Erb M, Hoffmann-Enger B, Deppe H, Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS One 2012;7(4):e36153
   PubMed Web of Science ®Google Scholar
• Orssaud C, Robert M, Roche O, Dufier JL. Visual function improvement after idebenone therapy in Leber hereditary optic neuropathy. Acta Ophthalmol 2012; doi:10.1111/j.1755-3768.2012.T137.x
   Google Scholar
• Jancic J. Effectiveness of idebenone therapy in Leber's hereditary optic neuropathy (Meeting Abstract). Eur Neuropsychopharmacol 2011;21(2):S175
   Google Scholar